Literature DB >> 16389186

New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?

Paul H Sugarbaker1.   

Abstract

Appendiceal mucinous neoplasms sometimes present with peritoneal dissemination, which was previously a lethal condition with a median survival of about 3 years. Traditionally, surgical treatment consisted of debulking that was repeated until no further benefit could be achieved; systemic chemotherapy was sometimes used as a palliative option. Now, visible disease tends to be removed through visceral resections and peritonectomy. To avoid entrapment of tumour cells at operative sites and to destroy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal chemotherapy with mitomycin at 42 degrees C. Fluorouracil is then given postoperatively for 5 days. If the mucinous neoplasm is minimally invasive and cytoreduction complete, these treatments result in a 20-year survival of 70%. In the absence of a phase III study, this new combined treatment should be regarded as the standard of care for epithelial appendiceal neoplasms and pseudomyxoma peritonei syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389186     DOI: 10.1016/S1470-2045(05)70539-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  169 in total

1.  Primary appendiceal mucinous adenocarcinoma alongside with situs inversus totalis: a unique clinical case.

Authors:  Athanasios Petrou; Alexandros Papalambros; Nikolaos Katsoulas; Konstantinos Bramis; Konstantinos Evangelou; Evaggelos Felekouras
Journal:  World J Surg Oncol       Date:  2010-06-04       Impact factor: 2.754

2.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

3.  Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.

Authors:  Haroon Asif Choudry; Arun Mavanur; Mark E O'Malley; Herbert J Zeh; Z Sheng Guo; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2012-05       Impact factor: 5.344

4.  Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.

Authors:  Frances Austin; Arun Mavanur; Magesh Sathaiah; Jennifer Steel; Diana Lenzner; Lekshmi Ramalingam; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2012-05       Impact factor: 5.344

Review 5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Surgical management of peritoneal carcinomatosis: from clinical research to standard of care.

Authors:  Santiago González-Moreno
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

7.  Appendiceal mucocoeles and pseudomyxoma peritonei.

Authors:  Anupam Dixit; John H P Robertson; Satvinder S Mudan; Charles Akle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

8.  Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique.

Authors:  Rebecca Fish; Chelliah Selvasekar; Peter Crichton; Malcolm Wilson; Paul Fulford; Andrew Renehan; Sarah O'Dwyer
Journal:  Surg Endosc       Date:  2013-09-06       Impact factor: 4.584

9.  The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre.

Authors:  Lawson Ung; Terence C Chua; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-21       Impact factor: 4.553

Review 10.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

Authors:  Wim P Ceelen; Michael F Flessner
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.